Evidence map›Paper›PMID 36454506›Full record

ArticleMetabolic brain disease2023

PD-L1 is required for estrogen-induced protection against severe EAE in IL-10 deficient mice

Halina Offner, Denesa Lockwood, Roberto Meza-Romero, Arthur A Vandenbark

Open access · greenAbstract read
In one paragraph

Article in Metabolic brain disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Halina OffnerDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA. offnerva@ohsu.edu.ORCID http://orcid.org/0000-0001-6472-6079
Denesa LockwoodDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA.
Roberto Meza-RomeroDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA.
Arthur A VandenbarkDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA.
Oregon Health & Science University · US

Funding

Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjectsR44AI122574 · NIAID · VIROGENOMICS BIODEVELOPMENT, INC. · PI SHIRLEY, RENEE LYNN, VANDENBARK, ARTHUR A. · 2020 to 2022
$3.0M
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjectsR42AI122574 · NIAID · VIROGENOMICS BIODEVELOPMENT, INC. · PI VANDENBARK, ARTHUR A. · 2017 to 2018
$1.5M
Compensatory mechanisms of estrogen mediated protection from EAE in IL-10 KO miceR21AI148409 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI OFFNER, HALINA · 2020 to 2021
$347k
Immunoregulation of Myelin-Specific T LymphocytesI01BX000226 · VA · PORTLAND VA MEDICAL CENTER · PI VANDENBARK, ARTHUR A. · 2009 to 2024
–
Preclinical Translational Studies with DRHQI01BX005112 · VA · PORTLAND VA MEDICAL CENTER · PI VANDENBARK, ARTHUR A. · 2020 to 2024
–
BLRD Research Career Scientist Award ApplicationIK6BX004209 · VA · PORTLAND VA MEDICAL CENTER · PI ARTHUR A. VANDENBARK · 2018 to 2026
–
BLRD VA I01 BX000226BLRD VA I01 BX005112BLRD VA IK6 BX004209National Institute of Allergy and Infectious Diseases AI148490National Institute of Allergy and Infectious Diseases AI22574NIAID NIH HHS R21 AI148409NIAID NIH HHS R42 AI122574NIAID NIH HHS R44 AI122574U.S. Department of Veterans Affairs BX000226U.S. Department of Veterans Affairs BX004209U.S. Department of Veterans Affairs BX005112
6 · The paper itself

Abstract

backgroundIL-10 knockout (KO) mice can be protected against experimental autoimmune encephalomyelitis (EAE) with low-dose estrogen (E2) treatment similar to wild type (WT) mice, indicating that IL-10 is not required for E2-induced EAE protection. Our previous study demonstrated that E2 treatment induced an increase in programmed death ligands 1 (PD-L1) and 2 (PD-L2) on monocytes and macrophages in the periphery and within the CNS. In this study, we selectively inhibited the function of PD-L1 and PD-L2 to evaluate their critical role in maintaining E2-induced protection against EAE in IL-10-KO mice.

methodsThis study used female IL-10 KO mice pre-treated with either E2 or sham pellets seven days prior to induction of EAE and subsequently treated with Vehicle or antibodies to PD-L1, PD-L2 or respective isotype controls. Mice were scored daily for EAE severity over 21 days post-EAE induction. Cells from the spleen and brain were evaluated by flow cytometry.

resultsDifferences in EAE severity were assessed in E2 and sham pre-treated IL-10-KO mice treated with α-PD-L1 or α-PD-L2 antibodies over the course of disease compared to treatment with Vehicle or isotype control antibodies. The results revealed real-time development of severe EAE in E2-pre-treated IL-10-KO mice treated with α-PD-L1 but not α-PD-L2 antibodies, mediated in part by increased percentages of activated CD74

conclusionThese results demonstrate unequivocally that PD-L1 but not PD-L2 was required to retain the inhibitory effects of E2 on clinical EAE scores in female IL-10-KO mice and further implicate the emergence of the MIF/CD74 axis as a contributing pathogenic mechanism.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalAnimalsB7-H1 AntigenBrainEstrogensFemaleInterleukin-10MiceMice, Inbred C57BLMice, KnockoutB7-H1 AntigenCd274 protein, mouseEstrogensIL10 protein, mouseInterleukin-10EAE inhibitionEstrogen (E2), PD-1 ligandIL-10Regulatory B, T and myeloid cells

Identifiers

PMID36454506
PMCPMC9976593
OpenAlexW4310573314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.